Pfizer vaccine 97% effective against symptomatic coronavirus infection: study

Pfizer and BioNTech’s coronavirus vaccine offers more protection than earlier thought with its efficacy in preventing symptomatic infection reaching 97%, consistent with real-world evidence published Thursday by pharmaceutical companies.

Using data from January 17 to March 6 from Israel’s national vaccination campaign, Pfizer and BioNTech found that prevention against asymptomatic disease also reached 94%.

An earlier real-world study using data from between December 20, 2020, and February 1, 2021, had shown effectiveness at preventing symptomatic disease at 94% and asymptomatic illness at 92%.

“This comprehensive real-world evidence … are often of importance to countries round the world as they advance their own vaccination campaigns one year after the planet Health Organisation declared COVID-19 an epidemic ,” the 2 pharmaceutical companies said during a statement.

Israel’s inoculation campaign is that the fastest within the world, with about 40% of the population already fully vaccinated against the virus.

Israel, which launched its vaccination campaign in December, has given the recommended two jabs of the Pfizer/BioNTech vaccine to only under four million of its roughly nine million people.

More than five million have received round .

“Incidence rates within the fully vaccinated population have massively dropped compared to the unvaccinated population, showing a marked decline in hospitalised cases thanks to COVID-19,” said Israel´s Ministry of Health director Yeheskel Levy.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button